Trial of rPA-102 Vaccine in Healthy Adult Volunteers
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the safety and immunogenicity of rPA102 vaccine given intramuscularly at 0 and 4 weeks over 2 dose ranges and 4 adjuvant levels.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Outcome Measures
Primary Outcome Measures
- Safety and immune response to vaccine. []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Able to understand the study and give written informed consent. A signed informed consent must be in place before the initiation of any study interventions.
-
Healthy male or female aged 18-55 years old (inclusive) without significant physical or clinical laboratory abnormalities.
-
Two intact upper arms with sufficient intramuscular (IM) tissue in the deltoid region for vaccine administration.
-
For females, negative serum pregnancy test at screening and agreement to use adequate birth control during the first 2 months of the study.
-
Willingness and ability to return for all follow-up visits and blood draws for the duration of the study.
-
Willingness to complete the Volunteer Diary and to report concomitant medications and adverse events (AEs) to the study site monitors during the study period.
Exclusion Criteria:
-
Prior history of, or known exposure to any form of B. anthracis or any anthrax immunization.
-
Member of the Armed Services (Active Duty or Reserve) since 1990, with history of previous anthrax vaccination.
-
Employment in an industry involved in contact with ruminant animals, veterinary sciences, or other exposure to B. anthracis, or emergency first responders.
-
Expected to be noncompliant with study visits or planning to move within 12 months.
-
Body mass index of >35 or <19.
-
Known allergy to aluminum hydroxide, kanamycin, or any other aminoglycoside antibiotics (such as gentamicin).
-
Pregnancy (positive urine pregnancy test within 24 hours prior to vaccination), or lactation.
-
HIV positive (by history or screening ELISA).
-
Hepatitis B or C positive (by history or screening HBsAg/anti-HCV ELISA).
-
Active or past internal organ, hematologic malignancy, or metastatic cutaneous malignancy.
-
History of, or current autoimmune disease, including but not limited to systemic lupus erythematosus, scleroderma, and polyarteritis.
-
Immunodeficiency or unstable medical condition as determined by baseline medical history, physical exam, and laboratory assessment.
-
Received or plans to receive licensed live vaccines within 30 days of study vaccination.
-
Received or plans to receive licensed killed vaccines within 14 days of study vaccination.
-
Received or plans to receive immunoglobulin or other blood products within 60 days of study vaccination.
-
Received or plans to receive experimental drugs/vaccines within 30 days prior to, and for the duration of the study.
-
Received or plans to receive systemic immunosuppressive therapy, radiation therapy, or high-dose inhaled steroids within 30 days of study vaccination.
-
Use of systemic chemotheraphy within 5 years prior to study.
-
History of Guillain-Barre Syndrome.
In addition to the conditions listed above, the following may qualify as a reason to exclude a volunteer from the study: fever along with moderate or serious illness within 3 days of vaccination or any condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the study evaluations. Pending resolution of these symptoms, a volunteer may be reconsidered for vaccination.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UCLA Ctr for Vaccine Research, LA Biomedical Research Institute | Torrance | California | United States | 90502 |
| 2 | Emory Children's Clinic, Pediatric Infectious Disease | Atlanta | Georgia | United States | 30322 |
| 3 | University of Kentucky, Markey Cancer Center | Lexington | Kentucky | United States | 40536-0093 |
| 4 | Johns Hopkins University, Bloomberg School of Public Health | Baltimore | Maryland | United States | 21205 |
| 5 | Mayo Clinic College of Medicine | Rochester | Minnesota | United States | 55905 |
| 6 | St. Louis University, SoLUtions | St. Louis | Missouri | United States | 63104 |
| 7 | Infectious Disease Unit, University of Rochester Medical Center | Rochester | New York | United States | 14642 |
| 8 | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | United States | 45229-3039 |
| 9 | Pediatric Clinical Trials Int'l, Inc. (PCTI) | Columbus | Ohio | United States | 43205 |
| 10 | Primary Physicians Research, Inc. | Pittsburgh | Pennsylvania | United States | 15241 |
| 11 | Vanderbilt University Medical Center | Nashville | Tennessee | United States | 37232 |
| 12 | University of Vermont College of Medicine, Vermont Vaccine Evaluation Center | Burlington | Vermont | United States | 05405 |
Sponsors and Collaborators
- VaxGen
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Centers for Disease Control and Prevention
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VAX006